Two-dose, inactivated vaccine

Development status

  1. Emergency use/conditional marketing authorizations granted in multiple countries
  2. Phase 3 clinical trials underway in Argentina, Egypt, Jordan and Peru
countries with procurement contracts

Emergency use
authorizations granted in:

Drugs to Watch - BBIBP-CorV Placeholder
Drugs to Watch - BBIBP-CorV


The vaccine is easily distributed and stored.

While it has a reported 79% efficacy when administered per protocol, it is associated with a lower cost that could be attractive to low-income countries.

Drugs to Watch 2021

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team